Rational design of boropeptide thrombin inhibitors: β,β-Dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 3, 1998, Pages 301-306

  Fevig, John M ^a   Buriak Jr , Joseph ^a   Cacciola, Joseph ^a   Alexander, Richard S ^a   Kettner, Charles A ^a   Knabb, Robert M ^a   Pruitt, James R ^a   Weber, Patricia C ^a,b   Wexler, Ruth R ^a  

^a DUPONT COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; COMPLEMENT; COMPLEMENT FACTOR I; ORGANOBORON DERIVATIVE; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONFORMATION; DRUG DESIGN; DRUG SYNTHESIS; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTITHROMBINS; BORON COMPOUNDS; COMPLEMENT FACTOR I; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MODELS, MOLECULAR; OLIGOPEPTIDES; RATS;

ANIMALIA;

EID: 0032477690     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00013-4     Document Type: Article

References (19)

1. 1. Presented in part at the 212th ACS National Meeting, Orlando, FL, August 25-29, 1996, MEDI 127.
2. 2. Das, J.; Kimball, S. D. Bioorg. Med. Chem. 1995, 3, 999.
3. 3. (a) Kettner, C.; Mersinger, L.; Knabb, R. J. Biol. Chem. 1990, 265, 18289.
4. (b) Knabb, R. M.; Kettner, C. A.; Timmermans, P. B. M. W. M.; Reilly, T. M. Thromb. Haemostas. 1992, 67, 56.
5. 4. For preliminary accounts of this work, see: (a) Kettner, C.; Knabb, R.; Fevig, J.; Hugli, T.; Lee, S.; Mantri, P.; Pangburn, M.; Reilly, T.; Stouten, P.; Thoolen, M.; Weber, P.; Wexler, R. Book of Abstracts 212th ACS National Meeting, Orlando, FL, August 25-29, 1996, MEDI 112;
6. (b) Knabb, R. M.; Luettgen, J. M.; Leamy, A. W.; Barbera, F. A.; Kettner, C. A.; Pangburn, M. K.; Thoolen, M. J. Circulation 1996, 94, Suppl. I, 696. Full details will be reported elsewhere.
7. 5. Thon, I. L.; Uvnas, B. Acta Physiol. Scand. 1967, 71, 303.
8. 6. Cochrane, C. G.; Mueller-Eberhard, H. J.; Aikin, B. S. J. Immunol. 1970, 105, 55.
9. 7. Pangburn, M. K.; Muller-Eberhard, H. J. Biochemistry 1983, 22, 178.
10. 8. Verbeuren and co-workers have also reported on the relationship between factor I selectivity and toxicity for a series of boronic acid thrombin inhibitors. See: Rupin, A.; Mennecier, P.; Lila, C.; de Nanteuil, G.; Verbeuren, T. J. Thromb. Haemostas. 1997, 78, 1221.
11. 9. Perkins, S. J.; Smith, K. F. Biochem J. 1993, 295, 109.
12. 10. Bode, W.; Turk, D.; Karshikov, A. Protein Sci. 1992, 426.
13. 11. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park, C. H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. J. Mol. Biol. 1993, 232, 947.
14. 12. Galemmo, R. A., Jr.; Fevig, J. M.; Carini, D. J.; Cacciola, J.; Wells, B. L.; Hillyer, G. L.; Buriak, J., Jr.; Rossi, K. A.; Stouten, P. F. W.; Alexander, R. S.; Hilmer, R.; Bostrom, L.; Abelman, M. M.; Lee, S.-L.; Weber, P. C.; Kettner, C. A.; Knabb, R. M.; Wexler, R. R. Bioorg. Med. Chem. Lett. 1996, 6, 2913.
15. factor of 20%.
16. 14. Burtey, S. K.; Petsko, G. A. Science 1985, 229, 23.
17. 15. Satisfactory spectral data were obtained for all new compounds.
18. 16. Wityak, J.; Earl, R. A.; Abelman, M. M.; Bethel, Y. B.; Fisher, B. N.; Kauffman, G. S.; Kettner, C. A.; Ma, P.; McMillan, J. L.; Mersinger, L. J.; Pesti, J.; Pierce, M. E.; Rankin, F. W.; Chorvat, R. J.; Confalone, P. N. J. Org. Chem. 1995, 60, 3717.
19. 17. For an example of this type of binding in a closely related compound, see: Strickland, C. L.; Fevig, J. M.; Galemmo, R. A., Jr.; Wells, B. L.; Kettner, C. A.; Weber, P. C. Acta Crystallographica Section D, in press.